ROS1 is a receptor tyrosine kinase of the insulin receptor family, the overexpression of overactivity of ROS1 fusion proteins, due to chromosomal rearrangement, are associated with variety of cancers, including glioblastomas, lung cancer. The identification of ROS1 fusion genes as driver genes have broaden the anticancer indication of variety of the inhibitors of other targets, such as Crizotinib, Alectinib, Ceritinib and Brigatinib, which can also inhibit the activation of ROS1.
Ba/F3 cell, a murine interleukin-3 dependent pro-B cell line, is a popular system for exploring both kinases and their inhibitors, because some protein kinases can render the Ba/F3 cells to be depended on the activation of the kinases instead of IL-3 supplement, while their inhibitors can antagonize the kinase-dependent growth effects.